2022 saw continued investment in emerging players and big strategic bets by many established life sciences software platforms. From clinical discovery to commercialization, advancing digital solutions remains central to pharma and med device manufacturers. The plethora of real world evidence data collected pre-market and post-market continues to demand innovation and a data analytics ecosystem where both software and services players co-exist. We are excited about the huge potential for further strategic consolidation and high growth opportunities for many new entrants.
Madison Park Group actively tracks the life sciences software and services landscape and has been instrumental in strategic deals across the drug development & commercialization spectrum. We’ve noticed a number of recent trends and developments:
- Commercialization services remain in high demand amidst rapid drug development and market launch efforts, leading to sustained M&A and investment activity in the ecosystem
- Data and analytics remain a top priority for the life sciences market, as organizations seek insights to drive efficiencies across pre- and post-market functions
- Patient recruitment and retention within trials remain key challenges; hurdles include patient / trial matching, complex consent forms, logistics and disciplined medication adherence
- As live events return, content, learning and events technology vendors are converging to create end-to-end solutions for driving HCP education and compliant pharma promotional activities